Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market size was valued at USD 9869.6 million in 2023 and is forecast to a readjusted size of USD 24800 million by 2030 with a CAGR of 14.1% during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry chain, the market status of Oncology (PCR, In-situ Hybridization), Neurological Disorders (PCR, In-situ Hybridization), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Regionally, the report analyzes the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PCR, In-situ Hybridization).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market.
Regional Analysis: The report involves examining the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx):
Company Analysis: Report covers individual Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Neurological Disorders).
Technology Analysis: Report covers specific technologies relevant to Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx). It assesses the current state, advancements, and potential future developments in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) from 2019 to 2024.
Chapter 3, the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Chapter 13, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) research findings and conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry chain, the market status of Oncology (PCR, In-situ Hybridization), Neurological Disorders (PCR, In-situ Hybridization), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Regionally, the report analyzes the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PCR, In-situ Hybridization).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market.
Regional Analysis: The report involves examining the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx):
Company Analysis: Report covers individual Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Neurological Disorders).
Technology Analysis: Report covers specific technologies relevant to Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx). It assesses the current state, advancements, and potential future developments in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- PCR
- In-situ Hybridization
- Immunohistochemistry
- Sequencing
- Others
- Oncology
- Neurological Disorders
- Cardiovascular Disease
- Immunological Disorders
- Others
- Qiagen NV
- GE Healthcare
- Agilent Technologies
- F Hoffman La Roche
- Foundation Medicine
- Thermo Fisher Scientific Inc.
- Leica Biosystems Nussloch GmBH
- Pfizer
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) from 2019 to 2024.
Chapter 3, the Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx).
Chapter 13, to describe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Type
1.3.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type in 2023
1.3.3 PCR
1.3.4 In-situ Hybridization
1.3.5 Immunohistochemistry
1.3.6 Sequencing
1.3.7 Others
1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Application
1.4.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oncology
1.4.3 Neurological Disorders
1.4.4 Cardiovascular Disease
1.4.5 Immunological Disorders
1.4.6 Others
1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size & Forecast
1.6 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast by Region
1.6.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region, (2019-2030)
1.6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.6 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Qiagen NV
2.1.1 Qiagen NV Details
2.1.2 Qiagen NV Major Business
2.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Qiagen NV Recent Developments and Future Plans
2.2 GE Healthcare
2.2.1 GE Healthcare Details
2.2.2 GE Healthcare Major Business
2.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GE Healthcare Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 F Hoffman La Roche
2.4.1 F Hoffman La Roche Details
2.4.2 F Hoffman La Roche Major Business
2.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 F Hoffman La Roche Recent Developments and Future Plans
2.5 Foundation Medicine
2.5.1 Foundation Medicine Details
2.5.2 Foundation Medicine Major Business
2.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Foundation Medicine Recent Developments and Future Plans
2.6 Thermo Fisher Scientific Inc.
2.6.1 Thermo Fisher Scientific Inc. Details
2.6.2 Thermo Fisher Scientific Inc. Major Business
2.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
2.7 Leica Biosystems Nussloch GmBH
2.7.1 Leica Biosystems Nussloch GmBH Details
2.7.2 Leica Biosystems Nussloch GmBH Major Business
2.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Revenue
3.2.2 Top 3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share in 2023
3.2.3 Top 6 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share in 2023
3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Overall Company Footprint Analysis
3.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Region Footprint
3.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Type Footprint
3.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2024)
5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
6.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
6.3.3 Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
6.3.4 Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
7.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
7.3.2 Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.3 France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.5 Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.6 Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region
8.3.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2030)
8.3.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.4 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.5 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.7 Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
9.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
9.3 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
9.3.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
9.3.2 Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
9.3.3 Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
10.3.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
10.3.2 Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10.3.4 UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
11.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
11.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Chain
12.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Upstream Analysis
12.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Midstream Analysis
12.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Type
1.3.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type in 2023
1.3.3 PCR
1.3.4 In-situ Hybridization
1.3.5 Immunohistochemistry
1.3.6 Sequencing
1.3.7 Others
1.4 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market by Application
1.4.1 Overview: Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oncology
1.4.3 Neurological Disorders
1.4.4 Cardiovascular Disease
1.4.5 Immunological Disorders
1.4.6 Others
1.5 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size & Forecast
1.6 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast by Region
1.6.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region, (2019-2030)
1.6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.4 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.6 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Qiagen NV
2.1.1 Qiagen NV Details
2.1.2 Qiagen NV Major Business
2.1.3 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.1.4 Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Qiagen NV Recent Developments and Future Plans
2.2 GE Healthcare
2.2.1 GE Healthcare Details
2.2.2 GE Healthcare Major Business
2.2.3 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.2.4 GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 GE Healthcare Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.3.4 Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 F Hoffman La Roche
2.4.1 F Hoffman La Roche Details
2.4.2 F Hoffman La Roche Major Business
2.4.3 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.4.4 F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 F Hoffman La Roche Recent Developments and Future Plans
2.5 Foundation Medicine
2.5.1 Foundation Medicine Details
2.5.2 Foundation Medicine Major Business
2.5.3 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.5.4 Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Foundation Medicine Recent Developments and Future Plans
2.6 Thermo Fisher Scientific Inc.
2.6.1 Thermo Fisher Scientific Inc. Details
2.6.2 Thermo Fisher Scientific Inc. Major Business
2.6.3 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.6.4 Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
2.7 Leica Biosystems Nussloch GmBH
2.7.1 Leica Biosystems Nussloch GmBH Details
2.7.2 Leica Biosystems Nussloch GmBH Major Business
2.7.3 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.7.4 Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
2.8.4 Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Pfizer Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Revenue
3.2.2 Top 3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share in 2023
3.2.3 Top 6 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players Market Share in 2023
3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Overall Company Footprint Analysis
3.3.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Region Footprint
3.3.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Type Footprint
3.3.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value and Market Share by Type (2019-2024)
4.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2024)
5.2 Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
6.2 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
6.3 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
6.3.1 North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
6.3.2 United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
6.3.3 Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
6.3.4 Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
7.2 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
7.3 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
7.3.1 Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
7.3.2 Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.3 France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.5 Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
7.3.6 Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Region
8.3.1 Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2030)
8.3.2 China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.3 Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.4 South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.5 India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
8.3.7 Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
9.2 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
9.3 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
9.3.1 South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
9.3.2 Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
9.3.3 Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size by Country
10.3.1 Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2030)
10.3.2 Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
10.3.4 UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
11.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
11.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industry Chain
12.2 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Upstream Analysis
12.3 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Midstream Analysis
12.4 Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Qiagen NV Company Information, Head Office, and Major Competitors
Table 6. Qiagen NV Major Business
Table 7. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 8. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Qiagen NV Recent Developments and Future Plans
Table 10. GE Healthcare Company Information, Head Office, and Major Competitors
Table 11. GE Healthcare Major Business
Table 12. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 13. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GE Healthcare Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 18. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. F Hoffman La Roche Company Information, Head Office, and Major Competitors
Table 21. F Hoffman La Roche Major Business
Table 22. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 23. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. F Hoffman La Roche Recent Developments and Future Plans
Table 25. Foundation Medicine Company Information, Head Office, and Major Competitors
Table 26. Foundation Medicine Major Business
Table 27. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 28. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Foundation Medicine Recent Developments and Future Plans
Table 30. Thermo Fisher Scientific Inc. Company Information, Head Office, and Major Competitors
Table 31. Thermo Fisher Scientific Inc. Major Business
Table 32. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 33. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Thermo Fisher Scientific Inc. Recent Developments and Future Plans
Table 35. Leica Biosystems Nussloch GmBH Company Information, Head Office, and Major Competitors
Table 36. Leica Biosystems Nussloch GmBH Major Business
Table 37. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 38. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
Table 40. Pfizer Company Information, Head Office, and Major Competitors
Table 41. Pfizer Major Business
Table 42. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 43. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Pfizer Recent Developments and Future Plans
Table 45. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Players (2019-2024)
Table 46. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players (2019-2024)
Table 47. Breakdown of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 48. Market Position of Players in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 49. Head Office of Key Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players
Table 50. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Type Footprint
Table 51. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Application Footprint
Table 52. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) New Market Entrants and Barriers to Market Entry
Table 53. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Mergers, Acquisition, Agreements, and Collaborations
Table 54. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (USD Million) by Type (2019-2024)
Table 55. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Type (2019-2024)
Table 56. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Forecast by Type (2025-2030)
Table 57. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024)
Table 58. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Forecast by Application (2025-2030)
Table 59. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 60. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 61. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 62. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 63. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 64. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 65. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 66. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 67. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 68. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 69. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 70. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 71. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 72. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 73. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 74. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 75. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2024) & (USD Million)
Table 76. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2025-2030) & (USD Million)
Table 77. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 78. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 79. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 80. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 81. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 82. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 84. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 85. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 86. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 87. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 88. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 89. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Raw Material
Table 90. Key Suppliers of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Raw Materials
Table 1. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Qiagen NV Company Information, Head Office, and Major Competitors
Table 6. Qiagen NV Major Business
Table 7. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 8. Qiagen NV Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Qiagen NV Recent Developments and Future Plans
Table 10. GE Healthcare Company Information, Head Office, and Major Competitors
Table 11. GE Healthcare Major Business
Table 12. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 13. GE Healthcare Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. GE Healthcare Recent Developments and Future Plans
Table 15. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 16. Agilent Technologies Major Business
Table 17. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 18. Agilent Technologies Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Agilent Technologies Recent Developments and Future Plans
Table 20. F Hoffman La Roche Company Information, Head Office, and Major Competitors
Table 21. F Hoffman La Roche Major Business
Table 22. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 23. F Hoffman La Roche Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. F Hoffman La Roche Recent Developments and Future Plans
Table 25. Foundation Medicine Company Information, Head Office, and Major Competitors
Table 26. Foundation Medicine Major Business
Table 27. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 28. Foundation Medicine Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Foundation Medicine Recent Developments and Future Plans
Table 30. Thermo Fisher Scientific Inc. Company Information, Head Office, and Major Competitors
Table 31. Thermo Fisher Scientific Inc. Major Business
Table 32. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 33. Thermo Fisher Scientific Inc. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Thermo Fisher Scientific Inc. Recent Developments and Future Plans
Table 35. Leica Biosystems Nussloch GmBH Company Information, Head Office, and Major Competitors
Table 36. Leica Biosystems Nussloch GmBH Major Business
Table 37. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 38. Leica Biosystems Nussloch GmBH Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Leica Biosystems Nussloch GmBH Recent Developments and Future Plans
Table 40. Pfizer Company Information, Head Office, and Major Competitors
Table 41. Pfizer Major Business
Table 42. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Product and Solutions
Table 43. Pfizer Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Pfizer Recent Developments and Future Plans
Table 45. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue (USD Million) by Players (2019-2024)
Table 46. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players (2019-2024)
Table 47. Breakdown of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) by Company Type (Tier 1, Tier 2, and Tier 3)
Table 48. Market Position of Players in Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 49. Head Office of Key Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Players
Table 50. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Type Footprint
Table 51. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market: Company Product Application Footprint
Table 52. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) New Market Entrants and Barriers to Market Entry
Table 53. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Mergers, Acquisition, Agreements, and Collaborations
Table 54. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (USD Million) by Type (2019-2024)
Table 55. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Type (2019-2024)
Table 56. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Forecast by Type (2025-2030)
Table 57. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024)
Table 58. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Forecast by Application (2025-2030)
Table 59. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 60. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 61. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 62. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 63. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 64. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 65. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 66. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 67. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 68. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 69. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 70. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 71. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 72. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 73. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 74. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 75. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2019-2024) & (USD Million)
Table 76. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Region (2025-2030) & (USD Million)
Table 77. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 78. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 79. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 80. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 81. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 82. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2019-2024) & (USD Million)
Table 84. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type (2025-2030) & (USD Million)
Table 85. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2019-2024) & (USD Million)
Table 86. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Application (2025-2030) & (USD Million)
Table 87. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2019-2024) & (USD Million)
Table 88. Middle East & Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Country (2025-2030) & (USD Million)
Table 89. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Raw Material
Table 90. Key Suppliers of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Raw Materials
LIST OF FIGURES
Figure 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Picture
Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type in 2023
Figure 4. PCR
Figure 5. In-situ Hybridization
Figure 6. Immunohistochemistry
Figure 7. Sequencing
Figure 8. Others
Figure 9. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application in 2023
Figure 11. Oncology Picture
Figure 12. Neurological Disorders Picture
Figure 13. Cardiovascular Disease Picture
Figure 14. Immunological Disorders Picture
Figure 15. Others Picture
Figure 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Market Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 19. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region (2019-2030)
Figure 20. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region in 2023
Figure 21. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players in 2023
Figure 27. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 28. Global Top 3 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share in 2023
Figure 29. Global Top 6 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share in 2023
Figure 30. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Type (2019-2024)
Figure 31. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Type (2025-2030)
Figure 32. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Application (2019-2024)
Figure 33. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Application (2025-2030)
Figure 34. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 44. France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region (2019-2030)
Figure 51. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 54. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 68. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
Figure 69. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
Figure 70. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Manufacturing Cost Structure Analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) in 2023
Figure 73. Manufacturing Process Analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
Figure 74. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
Figure 1. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Picture
Figure 2. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type in 2023
Figure 4. PCR
Figure 5. In-situ Hybridization
Figure 6. Immunohistochemistry
Figure 7. Sequencing
Figure 8. Others
Figure 9. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 10. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application in 2023
Figure 11. Oncology Picture
Figure 12. Neurological Disorders Picture
Figure 13. Cardiovascular Disease Picture
Figure 14. Immunological Disorders Picture
Figure 15. Others Picture
Figure 16. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 17. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 18. Global Market Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 19. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region (2019-2030)
Figure 20. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region in 2023
Figure 21. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Revenue Share by Players in 2023
Figure 27. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 28. Global Top 3 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share in 2023
Figure 29. Global Top 6 Players Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share in 2023
Figure 30. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Type (2019-2024)
Figure 31. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Type (2025-2030)
Figure 32. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Share by Application (2019-2024)
Figure 33. Global Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Share Forecast by Application (2025-2030)
Figure 34. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 44. France Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Region (2019-2030)
Figure 51. China Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 54. India Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East and Africa Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Consumption Value (2019-2030) & (USD Million)
Figure 68. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Drivers
Figure 69. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Restraints
Figure 70. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Manufacturing Cost Structure Analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) in 2023
Figure 73. Manufacturing Process Analysis of Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx)
Figure 74. Pharmacogenomics Technology & Theranostics & Companion Diagnostics (CDx) Industrial Chain
Figure 75. Methodology
Figure 76. Research Process and Data Source
